We saw a significant decrease in cell viability in SMARCB1 deficient cell lines as compared to urothelial carcinoma cell line, JMSU1 (SWI/SNF wild type), or non-small cell lung cancer cell line, A549 (SMARCA4 mutant) (two-tailed t-test p-values 4.5e-5 and 4.6e-5; Figure 5c and Figure 5—figure supplement 1a). Here, SMARCB1 is linked to urothelial carcinoma.